(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with endomorphin 1 in 1 studies
| Studies ((e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide) | Trials ((e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide) | Recent Studies (post-2010) ((e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide) | Studies (endomorphin 1) | Trials (endomorphin 1) | Recent Studies (post-2010) (endomorphin 1) |
|---|---|---|---|---|---|
| 85 | 0 | 65 | 448 | 2 | 109 |
| Protein | Taxonomy | (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide (IC50) | endomorphin 1 (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.026 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0275 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0363 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benedek, G; Farkas, I; Horvath, G; Tuboly, G | 1 |
1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and endomorphin 1
| Article | Year |
|---|---|
The antinociceptive potency of N-arachidonoyl-dopamine (NADA) and its interaction with endomorphin-1 at the spinal level.
Topics: Acrylamides; Analgesics; Animals; Arachidonic Acids; Area Under Curve; Bridged Bicyclo Compounds, Heterocyclic; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Hot Temperature; Hyperalgesia; Injections, Spinal; Male; Oligopeptides; Pain Measurement; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Spinal Cord; TRPV Cation Channels | 2011 |